TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer

  • Authors:
    • Ana Coelho
    • Augusto Nogueira
    • Sílvia Soares
    • Joana Assis
    • Deolinda Pereira
    • Isabel Bravo
    • Raquel Catarino
    • Rui Medeiros
  • View Affiliations

  • Published online on: March 26, 2018     https://doi.org/10.3892/ol.2018.8354
  • Pages: 8165-8171
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Identification of mechanisms that influence the therapeutic response and survival in patients with cancer is important. It is known that the genetic variability of the host, including presence of genetic polymorphisms in genes involved in DNA damage response, serves a crucial role in the prognosis of these patients. The present hospital‑based retrospective cohort study aimed to evaluate the influence of TP53 Arg72Pro (rs1042522) polymorphism in the clinical outcome of 260 Caucasian patients diagnosed with cervical cancer and treated with concomitant radiotherapy and chemotherapy. The polymorphism genotyping was assessed using allelic discrimination by quantiative polymerase chain reaction. The results indicate that the TP53 Arg72Pro polymorphism did not significantly impact the response to therapy (P=0.571) nor disease‑free survival (P=0.081). However, the polymorphism did influence overall survival, as increased median survival time was observed for patients carrying Arg/Pro genotype when compared with patients with Arg/Arg and Pro/Pro genotypes (126 months vs. 111 months, respectively; P=0.047). To conclude, the present findings suggest that a pharmacogenomic profile based on the genetic background of patients, including the analysis of the TP53 genotypes, may individualize treatment nad assist in the selection of therapies that may improve clinical outcome and lower toxicity for the patients.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Coelho A, Nogueira A, Soares S, Assis J, Pereira D, Bravo I, Catarino R and Medeiros R: TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer. Oncol Lett 15: 8165-8171, 2018
APA
Coelho, A., Nogueira, A., Soares, S., Assis, J., Pereira, D., Bravo, I. ... Medeiros, R. (2018). TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer. Oncology Letters, 15, 8165-8171. https://doi.org/10.3892/ol.2018.8354
MLA
Coelho, A., Nogueira, A., Soares, S., Assis, J., Pereira, D., Bravo, I., Catarino, R., Medeiros, R."TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer". Oncology Letters 15.5 (2018): 8165-8171.
Chicago
Coelho, A., Nogueira, A., Soares, S., Assis, J., Pereira, D., Bravo, I., Catarino, R., Medeiros, R."TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer". Oncology Letters 15, no. 5 (2018): 8165-8171. https://doi.org/10.3892/ol.2018.8354